Absci's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Absci (ABSI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Absci vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 72,126M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-18.5% annualized vs trailing 12 months), vs holding steady (+1.0%) for its tracked peer group.
- Growth: Absci generated -46.4% revenue growth year over year in Q2 2026, vs 12.4% for its competitors combined.
- Profitability: Its -10,443.4% net margin compares with 18.2% for the peer group.
- Scale: Absci ranks #22 of 46 companies by market capitalization in the Medical Laboratories industry, holding 0.5% of industry market cap.
- Peer revenue share: Absci accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.01M compares with $1.32M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ABSI Sales vs. its Competitors, Q2 2026
Absci reported revenue contraction of 46.37 % year on year in Q2 2026, below its competitors' combined revenue growth of 12.35 %.
With a net margin of -10,443.40 %, Absci reported lower profitability than its competitors (18.15 %).
Absci generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Absci vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Absci reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Absci and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Absci Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (13) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Absci's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 9.0% year over year, combined, vs -46.4% for Absci. Absci's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Absci's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Absci Corp | - | No | No | Yes |
| Competitors combined (13) | ||||
| High-Confidence Competitors (17) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ABSI Stock Performance relative to its Competitors
ABSI Stock Performance relative to High-Confidence Competitors
ABSI Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Twist Bioscience Corporation | 282.9% | Outperformed |
| 3 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 4 | Fortrea Holdings Inc | 282.9% | Outperformed |
| 5 | Schrodinger Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Absci's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Absci's Comment on Competition and Industry Peers
Publicly Traded Peers of Absci Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Absci Corp |
1,678.65 | 1.56 |
 Amgen Inc |
252,798.00 | 38,903.00 |
 Moderna Inc |
105,073.99 | 2,228.00 |
 Regeneron Pharmaceuticals Inc |
96,330.43 | 16,896.20 |
 Illumina Inc |
33,271.70 | 4,538.00 |
 Incyte Corporation |
24,536.61 | 6,010.75 |
| SUBTOTAL | 535,739.51 | 72,127.52 |
Sign in to see all competitors of Absci Corp.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Absci Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Absci's Competitors Named by the Company
Competitive relationships identified from Absci reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Exscientia Limited | Company report | 85% |
| Relay Therapeutics, Inc. | Company report | 85% |
| Recursion Pharmaceuticals, Inc. | Company report | 85% |
| Generate Biomedicines, Inc. | Company report | 85% |
| Merck | Company report | 85% |
| Roche/Roivant | Company report | 85% |
| Xaira Therapeutics, Inc. | Company report | 85% |
| Pelage Pharmaceuticals | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Spyre | Company report | 85% |
| Xencor | Company report | 85% |
| Cosmo Pharmaceuticals | Company report | 85% |
| Hope Medicine | Company report | 85% |
| Sanofi/Teva | Company report | 85% |
| Veradermics | Company report | 85% |
| AbbVie | Company report | 85% |
| Sanofi | Company report | 85% |
| Roche | Company report | 85% |
| Alloy Therapeutics, Inc. | Company report | 85% |
| AbCellera Biologics Inc. | Company report | 85% |
| Adimab LLC | Company report | 85% |
| Berkeley Lights Inc. | Company report | 85% |
| Sutro Biopharma, Inc. | Company report | 85% |
| Insitro, Inc. | Company report | 85% |
| Selexis SA | Company report | 85% |
| TScan Therapeutics, Inc. | Company report | 85% |
| 3T Biosciences, Inc. | Company report | 85% |
| Ambrx Inc. | Company report | 85% |
| Lonza Group AG | Company report | 85% |
| Zymergen Inc. | Company report | 85% |
| Bolt Threads, Inc. | Company report | 85% |
| Ginkgo Bioworks, Inc. | Company report | 85% |
| Geltor, Inc. | Company report | 85% |
| Schrodinger Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
Company report basis, confidence, active dates and source counts for Absci's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Absci's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.43 % |
| Incyte Corporation | Reportable 100.00 % |
| Twist Bioscience Corporation | Reportable 100.00 % |
| Schrodinger Inc | Software 62.40 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Absci's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Absci Corp | 1,679 | 11,150 | -864,836 |
| Amgen Inc | 252,798 | 2,992,538 | 722,385 |
| Moderna Inc | 105,074 | 474,043 | -670,426 |
| Regeneron Pharmaceuticals Inc | 96,330 | 1,096,444 | 312,615 |
| Illumina Inc | 33,272 | 3,545,313 | 699,219 |
| Incyte Corporation | 24,537 | 2,113,486 | 141,846 |
| PEERS TOTAL | 534,061 | 1,315,735 | 196,807 |
Absci's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Illumina Inc | United States and Canada 56.42 % |
| Incyte Corporation | United States 92.15 % |
| Twist Bioscience Corporation | Americas 58.08 % |
| Schrodinger Inc | United States 66.78 % |
| Fortrea Holdings Inc | North America 47.14 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Absci's Position in Industry Market Structure
Market-capitalization share and concentration across all 41 companies in Absci's industry classification, broader than the peer set above. Market cap in millions of $.Absci ranks #22 of 41 companies by market capitalization in its industry, holding 0.47 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 801, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Iqvia Holdings Inc | 46,005 | 12.88 % |
| 2 | Natera Inc | 45,226 | 12.66 % |
| 3 | Ge Healthcare Technologies Inc | 37,736 | 10.56 % |
| 4 | Labcorp Holdings Inc | 30,068 | 8.42 % |
| 5 | Quest Diagnostics Inc | 1,234 | 5.2% |
| 6 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 7 | Incyte Corporation | 1,234 | 5.2% |
| 8 | Guardant Health Inc | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
| 22 | Absci Corp | 1,679 | 0.47 % |
Market cap and industry share for the rest of Absci's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Absci's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 17 | Viridian Therapeutics Inc | 3,143 | 12.06 % |
| 18 | Veracyte Inc | 2,083 | -39.13 % |
| 19 | Fortrea Holdings Inc | 2,061 | 93.24 % |
| 20 | Butterfly Network Inc | 1,738 | 197.31 % |
| 21 | Personalis Inc | 1,234 | 12.3% |
| 22 | Absci Corp | 1,679 | 219.64 % |
| 23 | Lumexa Imaging Holdings Inc | 1,234 | 12.3% |
| 24 | Castle Biosciences Inc | 1,234 | 12.3% |
| 25 | Fulgent Genetics Inc | 1,234 | 12.3% |
| 26 | Lightwave Logic Inc | 1,234 | 12.3% |
| 27 | Omniab Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Absci's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Absci's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 33.04 % (avg) | -33.0 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -4.66 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 57.01 % | 7.45 % (avg) | +49.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Absci's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.0x | - |
| EV / EBITDA | - | 20.9x | - |
| P/B | 4.3x | 4.3x | +0.1x |
| Return on Equity | -59.21 % | industry aggregate | -70.52 % |
| Return on Invested Capital | -30.20 % | -7.64 % (avg) | -22.56 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Absci's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | -0.50 % | -20.71 % | -38.24 % |
| Operating Margin | - | -1,857.49 % | - | - | - |
| Return on Invested Capital | - | -17.00 % | -26.63 % | -25.39 % | -30.29 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Absci's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Absci falls in the Dog quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 5.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Absci's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 801 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 57.01 % vs industry average 7.45 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Absci's dedicated Suppliers and Customers pages, not here.
Absci's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Absci falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Absci's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 70.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-18.5% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.04x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (38.50 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Absci's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Absci Corp | 1.59 | 7.22 | 0.00 |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Illumina Inc | - | 2.02 | 0.68 |
| Incyte Corporation | 2.40 | 3.83 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Absci's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Absci Corp | Q2 2026 | -46.4 % | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Illumina Inc | Q3 2026 | +4.2 % | +46.7 % |
| Incyte Corporation | Q3 2026 | +14.0 % | - |
| PEERS TOTAL | +14.3 % | +1.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Absci's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Absci Corp | Q2 2026 | - | -99.6 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Illumina Inc | Q3 2026 | -14.8 % | +29.0 % |
| Incyte Corporation | Q3 2026 | +9.8 % | -60.7 % |
Absci's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Absci Corp | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Moderna Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Illumina Inc | 13.43% | 18.74% | 31.45% |
| Incyte Corporation | 5.48% | 6.81% | 7.08% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Absci's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Absci Corp | - | 1,075.37 |
| Amgen Inc | 26.84 | 6.50 |
| Moderna Inc | - | 47.16 |
| Regeneron Pharmaceuticals Inc | 20.18 | 5.70 |
| Illumina Inc | 37.31 | 7.33 |
| Incyte Corporation | 63.21 | 4.08 |
| PEERS AVERAGE | 50.22 | 7.43 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.